Abstract
Parkinson disease is a devastating neurodegenerative disorder with no known cure. Impairment in mitochondrial dysfunction is thought to play a major role in the pathogenesis. Recent genetic advances suggest that mitochondrial dysfunction may be the primary defect. Drugs that target the mitochondria may therefore represent the best hope for disease-modifying therapies in Parkinson disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Humans
-
Intracellular Signaling Peptides and Proteins / genetics
-
Mitochondria / genetics
-
Mitochondria / pathology*
-
Mitochondrial Diseases* / complications
-
Mitochondrial Diseases* / genetics
-
Mitochondrial Diseases* / pathology
-
Models, Biological
-
Oncogene Proteins / genetics
-
Parkinson Disease / etiology
-
Parkinson Disease / genetics
-
Parkinson Disease / pathology*
-
Protein Deglycase DJ-1
-
Protein Kinases / genetics
Substances
-
Intracellular Signaling Peptides and Proteins
-
Oncogene Proteins
-
Protein Kinases
-
PTEN-induced putative kinase
-
PARK7 protein, human
-
Protein Deglycase DJ-1